LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that a review of ganetespib results in non-small cell lung cancer (NSCLC) was presented by Dr. Suresh Ramalingam, Associate Professor, Chief of Thoracic Oncology and Director of Medical Oncology, Emory University, at the International Association for the Study of Lung Cancer (IASLC) 12th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. Results showed that ganetespib is active in non-small cell lung cancer; has a favorable safety profile as a monotherapy or in combination with docetaxel; shows evidence of synergy with docetaxel in preclinical models; and has pronounced single-agent clinical activity in ALK+ lung cancer, which is believed to be complementary to, rather than competitive with, direct ALK kinase inhibitors such as crizotinib.
